6533b7d8fe1ef96bd126ad3f
RESEARCH PRODUCT
Clinical factors leading to lamotrigine prescription in bipolar outpatients: Subanalysis of the SIN-DEPRES study
F.g. Iglesias LorenzoIria GrandeJ.i. Franch ValverdeEduard VietaVicent Balanzá-martínezS. ZaragozaSilvia CobaledaR. De ArceMa. Jiménez-arrierosubject
AdultMalemedicine.medical_specialtyBipolar DisorderLamotrigineLamotrigineLogistic regressionBipolar II disorderAntimanic AgentsRating scaleInternal medicineOutpatientsmedicineHumansProspective StudiesBipolar disorderMedical prescriptionPsychiatryDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressive DisorderTriazinesbusiness.industryMiddle Agedmedicine.diseasePsychiatry and Mental healthClinical PsychologyClinical Global ImpressionRegression AnalysisFemaleGuideline Adherencebusinessmedicine.drugdescription
Abstract Background The use of lamotrigine is a point of discrepancy among the diverse guidelines published on the management of bipolar disorder (BD). Evidence supporting the long-term efficacy is reasonably robust. Nonetheless, the effectiveness of lamotrigine in acute treatment is vigorously debated and it is unclear how this drug is used in routine clinical practice. This subanalysis of the SIN-DEPRES study was designed to understand the clinical profile of bipolar patients receiving lamotrigine. Methods In this prospective national multicenter study, 652 patients with clinically stable bipolar I and II disorder were recruited. Clinical assessments included sociodemographic and clinical data, the Modified Clinical Global Impression scale for BD (CGI-BP-M), the Hamilton Depression Rating Scale (HDRS), and prescriptions of psychotropic medications and their doses. Results By means of a logistic regression model, an association between receiving treatment with lamotrigine and the following clinical variables was found: number of past depressive episodes ( O.R. =2.875, 95% CI: 1.203–6.869, p =0.018), depressive polarity of the most recent episode ( O.R. =1.945, 95% CI: 1.267–2.985, p =0.002), severity in CGI-BD-M depression ( O.R. =1.850, 95% CI: 1.215−2.817, p =0.004), bipolar II disorder diagnosis ( O.R. =1.635, 95% CI: 1.078–2.482, p =0.021) and number of episodes per year ( O.R. =1.310, 95% CI: 1.069–1.605, p =0.009). Limitations Subanalysis of the SIN-DEPRES study with a cross-sectional design. Conclusions The use of lamotrigine in clinical practice is in accordance with most of the guidelines, which support its use in patients with depressive predominant polarity and bipolar II disorder.
year | journal | country | edition | language |
---|---|---|---|---|
2012-01-12 | Journal of Affective Disorders |